Document:

EX-10.1

 Exhibit 10.1 

February 28, 2022 
 Jason Meyenburg 

 

	Re:	 Separation Agreement and Release 

Dear Jason: 
 As discussed, this letter confirms
the terms of your separation from employment at Gemini Therapeutics, Inc. (the “Company”).1 As we agreed, your employment will end on February 28, 2022 (the
“Separation Date”). Consistent with the terms of your Employment Agreement with the Company, dated January 21, 2021 (the “Employment Agreement”), you shall be deemed to have resigned from all officer and
director positions that you hold with the Company upon the Separation Date, including as a member of the Board of Directors of the Company (the “Board”). Furthermore, in accordance with your Employment Agreement, the Company will
provide you with certain Severance Benefits (as defined below) following the end of your employment if you enter into, do not revoke, and comply with the terms and conditions of this letter agreement (this “Agreement”). 

In the interest of clarity, the following terms and conditions apply in connection with the end of your employment and regardless of whether
you enter into the Agreement: 
  

	 	•	 	 The Company will pay your salary and any accrued but unused vacation days to which you are entitled through the
Separation Date. 

  

	 	•	 	 The Company acknowledges that with respect to your eligibility under the Company’s annual cash incentive
bonus plan for calendar year 2021 and pursuant to Section 2(b) of the Employment Agreement, you are entitled to a bonus payment in the amount of $193,125 for calendar year 2021, which amount shall be paid in a lump sum no later than
March 15, 2022. 

  

	 	•	 	 The Company will make an employer contribution to your Healthcare Savings Account in the amount of $2,000 no
later than February 28, 2022. 

  

	 	•	 	 You will be able to continue group healthcare insurance coverage after the Separation Date under the law known as
“COBRA,” subject to eligibility requirements. Any COBRA continuation will be at your own cost, except as otherwise set forth herein if this Agreement becomes effective. 

 

	 	•	 	 Your eligibility to participate in any other employee benefit plans and programs of the Company will cease on or
after the Separation Date in accordance with applicable benefit plan or program terms and practices. 

  

	 	•	 	 The Company will reimburse you for any outstanding, reasonable business expenses you have incurred on the
Company’s behalf through the Separation Date in accordance with the Company’s expense reimbursement policy, after the Company’s timely receipt of appropriate documentation pursuant to such policy. 

 

	1 	 Except for the obligations set forth through the end of Section 2 hereof, which shall
be the sole obligation of Gemini Therapeutics, whenever the term “the Company” is used in this Agreement, it shall be deemed to include Gemini Therapeutics, Inc., Gemini Therapeutics Sub, Inc., and any other related companies (including,
without limitation, any divisions, affiliates, parents and subsidiaries of any of Gemini Therapeutics), and its and their respective officers, directors, employees, agents, successors and assigns. 

	 	•	 	 You will cease vesting in all of your stock options and other stock-based awards subject to vesting (the
“Equity Awards”) as of your Separation Date in accordance with the terms of the Equity Documents (as defined below), and you may exercise any vested portion of your options in accordance with the time limits and subject to the terms
of the applicable Equity Award agreement and equity plan (the “Equity Documents”) unless otherwise set forth herein if this Agreement becomes effective. Please contact the Chief Financial Officer with any questions regarding your
options. 

  

	 	•	 	 In accordance with Section 15 of the Employment Agreement, your obligations set forth in Sections 8 and 9 in
the Employment Agreement will continue after the Separation Date, except as otherwise set forth herein if this Agreement becomes effective. 

  

	 	•	 	 In accordance with Section 30 of the Employment Agreement, your obligations with respect to confidentiality
and assignment of inventions, as set forth in the agreement you signed when your employment began relating to such matters (the “Original Confidentiality Agreement”), will continue after the Separation Date. 

In addition to the above-described terms, you will be eligible to receive the Severance Benefits described in
Section 2, provided you enter into, do not revoke, and comply with this Agreement, including, but not limited to, signing and not revoking the Certificate Updating Release of Claims, attached hereto as Exhibit
A (the “Updated Release”). 
 The remainder of this letter proposes the Agreement between you and the Company. With
those understandings, you and the Company agree as follows: 
 1. Conditions. To receive the benefits described in this Agreement, you
must (i) enter into, not revoke, and comply with this Agreement, (ii) between now and the Separation Date, work with the Company to ensure the professional transition and wind down of your duties; and (iii) sign and not revoke the
Updated Release within seven (7) days of the end of the Advisory Termination Date (as defined below) (the “Conditions”). 

2. Severance Benefits. If you satisfy the Conditions, then the Company will provide you with the following
“Severance Benefits” following the Separation Date: 
 (a) Severance Pay. The Company will pay you an
amount equal to twelve (12) months of your current base salary, less standard payroll deductions and withholdings. 
 (b)
Health Benefits Continuation. If you timely and properly elect to receive benefits under COBRA, then the Company will pay all required premiums on a monthly basis for the same level of group healthcare coverage as in effect for you on the
Separation Date until the earliest of the following: (i) the twelve (12)-month anniversary of the Separation Date; (ii) your eligibility for group healthcare coverage through other employment; or (iii) the
cessation of your continuation rights under COBRA (the “Health Benefits Continuation Period”); provided, however, if the Company determines it cannot pay such amounts without potentially violating applicable law (including, without
limitation, Section 2716 of the Public Health Service Act), then the Company will convert such payments to payroll payments directly to you for the time period specified above. Such payments shall be subject to tax- related deductions and withholdings and paid on the Company’s regular payroll dates. You agree to notify the Company promptly if you become eligible for group healthcare coverage through another employer.
You may continue COBRA coverage after the end of the Health Benefits Continuation Period at your own expense for the remainder of the COBRA continuation period, subject to continued eligibility. 

 (c) Pro-Rated 2022 Bonus. The Company will
pay you a pro rata portion of the Target Bonus (as defined in the Employment Agreement) you earned for the current calendar year, measured from the first day of such calendar year through the Separation Date, in the total amount of $41,623.29. 

(d) Continued Vesting and Extended Exercise Period. Subject to the approval of the Board, (a) your Equity Awards shall continue to
vest until the later of your Separation Date or the end of your Service Relationship (as defined in the Company’s 2021 Stock Option and Incentive Plan or the Company’s 2017 Stock Option and Grant Plan, as applicable) (such date, the
“Vesting Termination Date”) and (b) the Company shall extend the exercise period with respect to your vested stock options until the earlier of (i) the original ten (10)-year expiration date for such vested stock options as
provided in the applicable Equity Documents, or (ii) 180 days after the Advisory Termination Date. 
 (e) Advisory Agreement. The
Company will enter into the Advisory Agreement attached hereto as Exhibit B with you (the “Advisory Agreement”), which will become effective on the Separation Date such that there is no break in your Service
Relationship with the Company for purposes of continued vesting in the Equity Awards. The date on which the Advisory Agreement is terminated for any reason shall be referred to herein as the “Advisory Termination Date”. The Advisory
Termination Date shall be no later than December 31, 2022. 
 (f) The amounts payable under Sections 2(a) and 2(c) above
shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over twelve (12) months commencing within thirty (30) days after the Effective Date (as defined below); provided, however, that if
there are any amounts still due to you under Sections 2(a) and 2(c) as of the Advisory Termination Date (such amounts, the “Remaining Severance Pay”), and provided that you satisfy the Conditions, the Remaining
Severance Pay shall be paid to you in a lump sum within thirty (30) days after the effective date of the Updated Release and in no event later than March 15, 2023. 

3. Restrictive Covenants. You and the Company acknowledge and agree that the
non-solicitation and non-competition restrictions in Section 8(h) of the Employment Agreement shall not apply, and that you are not entitled to any Garden Leave Pay
pursuant to the terms of Section 8(h)(iii) of the Employment Agreement. However, you agree that in connection with your separation from employment and in order to protect the Company’s Proprietary Information (as defined in the Employment
Agreement), goodwill, and other legitimate business interests, for a period of: (i) one (1) year following the end of the Advisory Termination Date, or (ii) two (2) years following the Advisory Termination Date if you breach your fiduciary
duty to the Company or if you have unlawfully taken, physically or electronically, property belonging to the Company (in either case the “Restricted Period”): 

(a) Non-Competition. You shall not, directly or indirectly, whether as owner, partner,
shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, anywhere in the world, engage or otherwise participate in any business that develops, manufactures or markets any
products, or performs any services, that are competitive with the products or services of the Company, including, without limitation, any products or services that the Company or its affiliates, has under development or were the subject of active
planning at any time during your employment, or any business engaged in the research, manufacturing, development or marketing of a recombinant Complement Factor H therapeutic and the performance of any services related to the foregoing (a
“Competing Business”). You acknowledge this covenant is necessary because the Company’s legitimate business interests cannot be adequately protected solely by the other covenants in this Agreement or the Employment Agreement.

 (b) Non-Solicitation of Customers, Prospects, or
Suppliers. You shall not, directly or indirectly, in any manner, solicit or transact any business with any of the customers or customer prospects of the Company or any of its suppliers. For purposes of this Agreement, (x) business shall
include any business that researches, develops, manufactures, markets, sells or distributes a product or service that competes with a product or service of the Company, (y) customers shall include then current customers to which the Company
provided products or services during the 12 months before the Advisory Termination Date (the “One Year Lookback”) and customer prospects shall include customer prospects the Company solicited during the One Year Lookback and with
which you had significant contact or about which you learned confidential information in the course of your employment, and (z) suppliers shall include then current suppliers and suppliers that provided services to or in connection with the
Company during the One Year Lookback. 
 (c) Non-Solicitation of Employees. You shall not,
directly or indirectly, in any manner, solicit, entice or attempt to persuade any employee of the Company to leave the Company for any reason or otherwise participate in or facilitate the hire, directly or through another entity, of any person who
is then employed by the Company. 
 (d) Non-Solicitation of Consultants. You shall not,
directly or indirectly, in any manner, solicit, entice or attempt to persuade any consultant of the Company to leave the Company in order to work for or otherwise engage with a Competing Business or otherwise participate in or facilitate the hire,
directly or through another entity, of any person who is then engaged by the Company to engage with or otherwise participate in a Competing Business. 
 You
agree that in the event you breach any of the restrictions under this Section 3, the remedies set forth in Section 12 of the Employment Agreement shall be available to the Company. 

4. Return of Property. You acknowledge and agree you are required to return all Company property in your possession to the
Company including, without limitation, Company-owned laptop, monitors, and docking station. Accordingly, by signing below, you acknowledge and agree you will comply with Section 8(f) of the Employment Agreement by returning to the Company on or
before the Advisory Termination Date (or sooner if requested by the Company) all Company property, including, without limitation, all files, reports, documents, laptops or other materials containing or pertaining to Proprietary Information (as
defined in the Employment Agreement) and to your work. After returning all of the foregoing, you commit to deleting and finally purging any duplicates of files or documents that may contain Company information from any
non-Company computer or other device that remains your property after the Advisory Termination Date. In the event you discover that you continue to retain any such information or property, you shall return it
to the Company immediately. 
 5. Non-Disparagement. Subject to Sections 8 and
10 of this Agreement, you agree to take no action or make any statements, written or oral, that are disparaging about or adverse to the business interests of the Company or its employees, directors, officers, agents, products, or services,
and the Company agrees to instruct the members of the Board and the executive leadership team to take no action or make any statements, written or oral, that are disparaging about or adverse to your professional reputation. This non-disparagement obligation shall not apply to truthful testimony in a legal proceeding. 
 6.
Communications. You will not communicate about your departure with anyone until after the Board has made a public written announcement about your departure (the “Company Announcement”); provided that you may communicate with
your tax advisors, attorneys and spouse about your departure before the Company Announcement, provided further that you first advise such persons not to reveal information about your departure and each such person agrees. The Company agrees that,
unless otherwise required by applicable law or regulation as determined by the Company in its reasonable good faith discretion, the Company shall give you an opportunity to review the Company Announcement prior to its publication. Once the Company
has made the Company Announcement, you agree to limit any communications regarding your departure to statements consistent with the Company Announcement. 

 7. Release of Claims. In consideration for, among other terms, the opportunity
to receive the Severance Benefits, to which you acknowledge you would otherwise not be entitled, you voluntarily release and forever discharge the Company, its affiliated and related entities, its and their respective predecessors, successors and
assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the current and former officers, directors, shareholders, employees, attorneys, accountants and agents of each of the foregoing in their official and
personal capacities (collectively referred to as the “Releasees”) generally from all claims, demands, debts, damages and liabilities of every name and nature, known or unknown (“Claims”) that, as of the date when
you sign this Agreement, you have, ever had, now claim to have or ever claimed to have had against any or all of the Releasees. This release includes, without limitation, all Claims: 

 

	 	•	 	 relating to your employment by the Company and the end of your employment with the Company;

  

	 	•	 	 of wrongful discharge or violation of public policy; 

 

	 	•	 	 of breach of contract; 

 

	 	•	 	 of defamation or other torts; 

 

	 	•	 	 of retaliation or discrimination under federal, state, or local law (including, without limitation, Claims of
discrimination or retaliation under the Age Discrimination in Employment Act; the Americans with Disabilities Act; Title VII of the Civil Rights Act of 1964; and the Massachusetts Fair Employment Practices Act); 

 

	 	•	 	 under the Massachusetts Civil Rights Act, the Massachusetts Equal Rights Act, the Massachusetts Labor and
Industries Act, the Massachusetts Payment of Wages Act, the Massachusetts Privacy Act, the Massachusetts Parental Leave Act, the Massachusetts Domestic Violence Leave Act, the Massachusetts Sick Leave Act, and the Massachusetts Paid Family and
Medical Leave Act; 

  

	 	•	 	 under any other federal or state statute (including, without limitation, Claims under the Fair Labor Standards
Act); 

  

	 	•	 	 for wages, bonuses, incentive compensation, stock, stock options, vacation pay, or any other compensation or
benefits, either under the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, §§ 148-150C, or otherwise; and 

 

	 	•	 	 for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages,
injunctive relief and attorney’s fees. 

 You agree and acknowledge you are waiving and releasing any claims for
unpaid wages of any type you may have against the Company under the Massachusetts Payment of Wages Act, M.G.L. c. 149, § 148 et seq. 

Notwithstanding the foregoing or any other provision of this Agreement: (i) you are not releasing the Company from any obligation
expressly set forth in this Agreement; (ii) your right to file a claim with the Equal Employment Opportunity Commission (“EEOC”), National Labor Relations Board, or similar state agencies is expressly preserved, provided,
however, if you file such a claim, you waive the right to recover monetary damages and any other relief personal to you in connection with such claim; (iii) you are not waiving claims that cannot be waived by law, such as claims for
workers’ compensation or unemployment benefits; (iv) you retain rights to any vested benefits, such as vested equity or pension or retirement benefits, the rights to which are governed by the terms of the applicable plan documents;
(v) you retain the right to participate in any investigation by any government agency charged with enforcement of 

 
any law; (vi) you are not waiving or releasing claims arising solely after the execution of this Agreement; (vii) you are not waiving or releasing
non-termination related claims under the Employee Retirement Income Security Act (29 U.S.C. § 1001 et seq.), as amended; and (viii) you are not waiving or releasing any rights and/or claims you may
have under COBRA. 
 8. Protected Disclosures and Other Protected Actions. Nothing contained in this Agreement limits your
ability to file a charge or complaint with any federal, state, or local governmental agency or commission (a “Government Agency”). In addition, nothing contained in this Agreement limits your ability to communicate with any
Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, nor does anything contained in this Agreement apply to truthful testimony in litigation. If you file any charge or
complaint with any Government Agency and if the Government Agency pursues any claim on your behalf, or if any other third party pursues any claim on your behalf, you waive any right to monetary or other individualized relief (either individually or
as part of any collective or class action). 
 9. Tax Treatment. The Company shall undertake to make deductions, withholdings
and tax reports with respect to payments and benefits under this Agreement to the extent it reasonably and in good faith determines it is required to make such deductions, withholdings and tax reports. Nothing in this Agreement shall be construed to
require the Company to make any payments to compensate you for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit. The parties intend that payments under this Agreement
will be exempt from or comply with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”). To the extent that any provision of this Agreement is ambiguous as to its exemption from or compliance with
Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder are exempt from or comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate
payment for purposes of Treasury Regulation Section 1.409A 2(b)(2). The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred
compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

10. Consideration Period and OWBPA. It is the Company’s desire and intent to make certain you fully understand the
provisions and effects of this Agreement. To that end, the Company hereby advises you in writing to consult with legal counsel for the purpose of reviewing the terms of this Agreement, and you are being given the opportunity to do so. Because you
are over 40 years of age, you are granted specific rights under the Older Workers Benefit Protection Act (“OWBPA”), which prohibits discrimination on the basis of age. Among other things, the release set forth in
Section 7 is intended to release any rights you may have against the Company alleging discrimination on the basis of age under the Age Discrimination in Employment Act (“ADEA”), the OWBPA and state and local laws. You
acknowledge and understand the release in Section 7 does not cover rights or claims under the ADEA that may arise after the date you sign this Agreement. 

Consistent with the provisions of OWBPA, you have the opportunity to consider this Agreement for
twenty-one (21) days from your receipt of this Agreement before signing it (the “Consideration Period”). You and the Company agree that any changes to this Agreement, whether material or
immaterial, do not restart or otherwise affect the Consideration Period. Furthermore, consistent with OWBPA and M.G.L. c. 149, s. 24L, you may revoke your assent to this Agreement if, within seven (7) business days after the date you sign this
Agreement, you deliver a written notice of revocation to the Company. To be effective, such notice of revocation must be emailed within the seven (7)-business day period to the Vice President of Legal Affairs. On the eighth business day following
your execution of this Agreement without your revocation, it will become final and binding on all parties (the “Effective Date”). 

 Also, consistent with the provisions of the OWBPA and other federal discrimination laws,
nothing in the release in Section 7 shall be deemed to prohibit you from challenging the validity of this release under the federal age or other discrimination laws (the “Federal Discrimination Laws”) or from filing a
charge or complaint of age or other employment related discrimination with the EEOC, or from participating in any investigation or proceeding conducted by the EEOC. However, the release in Section 7 does prohibit you from seeking or
receiving monetary damages or other individual-specific relief in connection with any such charge or complaint of age or other employment-related discrimination. Further, nothing in the release in Section 7 or this Agreement shall be
deemed to limit the Company’s right to seek immediate dismissal of such charge or complaint on the basis that your signing of this Agreement constitutes a full release of any individual rights under the Federal Discrimination Laws, or the
Company’s right to seek restitution or other legal remedies to the extent permitted by law of the economic benefits provided to you under this Agreement in the event that you successfully challenge the validity of this release and prevail in
any claim under the Federal Discrimination Laws. 
 By signing this Agreement, you acknowledge and agree: (i) but for providing the
waiver and release in Section 7, you would not be receiving the Severance Benefits being provided to you under the terms of this Agreement; (ii) you understand the various claims you are entitled to assert under the laws set forth
above; (iii) you have read this Agreement carefully and understand all its provisions; and (iv) the Company has advised you to consult with an attorney before signing this Agreement and to the extent you desired, you availed yourself of
this right. 
 11. Other Provisions 

(a) Attorneys’ Fees. The Company shall reimburse you for up to $5,000 in your reasonable attorneys’ fees actually incurred
with respect to having legal counsel review this Agreement, subject to the Company’s expense reimbursement policies and procedures. 

(b) Termination of Payments. In the event you fail to comply with any of your obligations under this Agreement, in addition to any
other legal or equitable remedies it may have for such breach, the Company shall have the right to discontinue providing you with the Severance Benefits. Any such consequences of a breach by you will not affect the release or your continuing
obligations under this Agreement or the Employment Agreement. 
 (c) Absence of Reliance. In signing this Agreement, you are not
relying upon any promises or representations made by anyone at or on behalf of the Company, except as set forth in this Agreement. 
 (d)
Jurisdiction. You and the Company hereby agree the state and federal courts in the Commonwealth of Massachusetts shall have the exclusive jurisdiction to consider any matters related to this Agreement, including without limitation any claim
of a violation of this Agreement. With respect to any such court action, you submit to the jurisdiction of such courts and you acknowledge venue in such courts is proper. 

(e) Governing Law; Interpretation. This Agreement shall be interpreted and enforced under the laws of the Commonwealth of
Massachusetts, without regard to conflict of law principles. In the event of any dispute, this Agreement is intended by the parties to be construed as a whole, to be interpreted in accordance with its fair meaning, and not to be construed strictly
for or against either you or the Company or the “drafter” of all or any portion of this Agreement. 

 (f) Enforceability. If any portion or provision of this Agreement (including, without
limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or
provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by
law. 
 (g) Waiver; Amendment. No waiver of any provision of this Agreement shall be effective unless made in writing and signed by
the waiving party. The failure of a party to require the performance of any term or obligation of this Agreement, or the waiver by a party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be
deemed a waiver of any subsequent breach. This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company. 

(h) Entire Agreement. This Agreement, together with its exhibits, constitutes the entire agreement between you and the Company with
respect to the subject matter hereof, and supersedes all prior agreements or understandings, both written and oral, between you and the Company with respect to the subject matter hereof, but does not in any way merge with or supersede the surviving
provisions of the Original Confidentiality Agreement, the Employment Agreement, or the Equity Documents, which agreements and obligations shall supplement, and shall not limit or be limited by, this Agreement. 

(i) Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be
taken to be an original, but all of which together shall constitute one and the same document. Electronic and pdf signatures shall be deemed to have the same legal effect as originals. 

[Signature Page Follows] 

 Please indicate your agreement to the terms of this Agreement by signing and returning to the Vice President
of Legal Affairs via PDF within the time period set forth above. 
  

							
	Very truly yours,	 		 	
			
	Gemini Therapeutics, Inc.	 		 	
				
	By:	 	/s/ Georges Gemayel	 		 	February 28, 2022
	Name:	 	Georges Gemayel, Ph.D.	 		 	Date
	Title:	 	Executive Chair	 		 	

 Enclosure (Employment Agreement; Original Confidentiality Agreement) 

This is a legal document. Your signature will commit you to its terms. By signing below, you acknowledge the Company has advised you to consult with counsel
prior to entering into this Agreement, you have carefully read and fully understand all of the provisions of this Agreement, and you are knowingly and voluntarily entering into this Agreement. 

 

					
	/s/ Jason Meyenburg	 		  	February 28, 2022
	Jason Meyenburg	 		  	Date

 EXHIBIT A 

CERTIFICATE UPDATING RELEASE OF CLAIMS 
 I,
Jason Meyenburg, hereby acknowledge and certify that I entered into a Separation Agreement and Release with Gemini Therapeutics, Inc. (the “Company”), dated February 28, 2022 (the “Agreement”). Capitalized
terms used herein and not otherwise defined have the meanings ascribed to such terms in the Agreement. Pursuant to the Agreement, and provided that I have satisfied the Conditions, I am required to execute this certificate, which updates the release
of claims set forth in Section 7 of the Agreement (this “Certificate”), in order to be eligible to receive or retain the Severance Benefits. I understand that I may not sign this Certificate until on or after the Advisory
Termination Date and I must return it to the Company within seven (7) days after the Advisory Termination Date as set forth below.  

I, therefore, agree as follows: 
  

	1.	 A copy of this Certificate was attached to the Agreement as Exhibit A. 

 

	2.	 In consideration of the benefits contained in the Agreement, including but not limited to the Severance
Benefits set forth in Section 2 of the Agreement, for which I become eligible only if I sign this Certificate, I hereby extend the release of claims set forth in Section 7 of the Agreement to any and all Claims that arose after the date I
signed the Agreement through the date I signed this Certificate, subject to all other exclusions and terms set forth in the Agreement. 

  

	3.	 I have carefully read and fully understand all of the provisions of this Certificate, I knowingly and
voluntarily agree to all of the terms set forth in this Certificate, and I acknowledge that in entering into this Certificate, I am not relying on any representation, promise or inducement made by the Company or its representatives with the
exception of those promises contained in this Certificate and the Agreement. 

  

	4.	 To receive or retain the Severance Benefits, I must return a signed, unmodified original or PDF copy of this
Certificate so that it is received by the Vice President of Legal Affairs within seven (7) days after the Advisory Termination Date. 

  

	5.	 I may revoke this Certificate within seven (7) days after I sign it by delivering a notice of revocation
to the Vice President of Legal Affairs. 

  

	6.	 If I do not sign the Certificate or if I revoke the Certificate, I will not be entitled to, or will forfeit my
right to retain, the Severance Benefits set forth in the Agreement. This Certificate shall become effective on the date that the Company receives an executed copy of the Certificate within the time frame set forth above. 

 

	7.	 I agree that this Certificate is part of the Agreement. 

 

					
	 	 		  	 
	Jason Meyenburg	 		  	Date

 EXHIBIT B 

ADVISORY AGREEMENT 
 This
Advisory Agreement (this “Agreement”) is effective as of February 28, 2022 (the “Effective Date”), by and between Gemini Therapeutics Sub, Inc., a Delaware corporation (the
“Company”), and Jason Meyenburg (the “Advisor”). 
 The Company desires to retain the
services of the Advisor and the Advisor desires to perform certain services for the Company. In consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged by the parties hereto, the parties agree as follows: 
  

	1.	 Services. 

During the Term (as defined below) of this Agreement, the Advisor shall provide services to the Company in exchange for certain consideration,
as described below. 
  

	 	1.1	 Advisor’s Services. The Advisor agrees to perform such consulting, advisory and related services to
and for the Company as may be reasonably requested from time to time by the Company, including, but not limited to, the services specified on Exhibit A (the “Services”). The Advisor agrees to perform the Services on an
as-needed basis, as requested by the Company, at such times and places as are mutually agreed upon by the Company and the Advisor. The Advisor shall use its best efforts, business judgment, and skill in
rendering the Services. 

  

	 	1.2	 Consideration. As full compensation for the Advisor’s Services provided under this Agreement, the
Company shall pay the Advisor as set forth on Exhibit B. In addition, for the sake of clarity, the Advisor’s outstanding stock options and other stock-based awards subject to vesting shall continue to vest during the Term (as defined
below) in accordance with the time limits and subject to the terms and conditions of the applicable equity award agreements and equity plan (collectively, the “Equity Documents”). 

 

	 	1.3	 Conflicts. Advisor represents and warrants that there exist no actual or potential conflicts of interest
concerning the Services to be performed under this Agreement, and that if any potential conflicts of interest arise during the Term, the Advisor shall advise the Company immediately. All Services and related documentation in connection with this
Agreement shall be kept completely separate from the Advisor’s other consulting, employment or research activities (as applicable). Advisor will not use the funding, resources and facilities of any other third party, without the prior written
consent of the Company, to perform Services hereunder. 

  

	 	1.4	 Expenses. If the Advisor is requested to travel on behalf of the Company, all necessary, reasonable, and
documented out-of-pocket expenditures incurred by the Advisor for travel shall be reimbursed by the Company. All such expenses shall be subject to pre-approval by the Company. The Company shall reimburse the Advisor’s properly incurred expenses within thirty (30) days of receipt of the invoice with supporting documentation. 

	 	1.5	 Independent Contractor Status. In providing the Services, the Advisor is acting in the capacity of an
independent contractor and not as an employee or agent of the Company. The Advisor has no authority to enter into contracts that bind the Company or to create obligations on the part of the Company. The Advisor shall not be entitled to participate
in the Company’s employee benefits programs. 

  

	 	1.6	 Taxes; Benefits. The Advisor shall have full responsibility for applicable taxes for all compensation
paid to the Advisor under this Agreement. To the extent that Advisor engages any employees or agents, Advisor shall be solely responsible for compliance with all applicable labor and employment laws and regulations. 

 

	 	1.7	 Legal Compliance. The Advisor shall comply with all laws, rules, and regulations applicable to its
activities in performing the Services. 

  

	2.	 Term and Termination. 

 

	 	2.1	 Term. Unless terminated earlier as provided in this Agreement, or extended by the written agreement of
both the Company and the Advisor, the term of this Agreement shall be for a period of three (3) months commencing on the Effective Date (the “Term”). In no event will the Term extend beyond December 31, 2022.

  

	 	2.2	 Termination. This Agreement may be terminated by either party thirty (30) days after written notice
to the other of intent to terminate. Notwithstanding the foregoing, the Company may immediately terminate this Agreement at any time if the Advisor breaches or threatens to breach any provision of this Agreement. Upon any early termination, the
Advisor shall be paid within thirty (30) days of such termination for any portion of the Services provided and for any expenses properly incurred pursuant to Section 1.4 prior to such early termination. 

 

	3.	 Confidentiality. 

 

	 	3.1	 Existing Obligations. The Advisor acknowledges and agrees that Advisor has existing obligations to the
Company, as set forth in the Employment Agreement, by and between Advisor and the Company, dated January 21, 2021 (the “Employment Agreement”), any other confidentiality, assignment of inventions or other restrictive
covenant agreement or obligation entered into by the Company and Advisor, and the Separation Agreement, by and between Advisor and Gemini Therapeutics, Inc, dated as of February 28, 2022 (the “Separation Agreement”,
collectively with the terms and conditions set forth in the Separation Agreement, the surviving terms and conditions of the Employment Agreement and the obligations referred to herein, the “Existing Obligations”). The Advisor
further acknowledges its relationship as an Advisor to the Company is one of high trust and confidence and in the course of performing the Services, Advisor will continue to have access to and contract with Proprietary Information (as defined in the
Employment Agreement) of the Company. Accordingly, the Advisor acknowledges and agrees that the Existing Obligations shall apply to its engagement under and the Services provided pursuant to this Agreement. 

	 	3.2	 Return of Property. Upon expiration or termination of this Agreement or at any other time upon request
by the Company, the Advisor shall promptly deliver to the Company all records, files, memoranda, notes, designs, data, reports, drawings, plans, sketches, laboratory and research notebooks and other documents (and all copies or reproductions of such
materials) relating to the Company, and any other Company property in Advisor’s possession, including the Company-owned laptop. 

  

	 	3.3	 Notice Pursuant to Defend Trade Secrets Act. Notwithstanding any provision of this Agreement prohibiting
the disclosure of trade secrets or other Proprietary Information, Advisor may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a
federal, state or local government official, either directly or indirectly, or to an attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law, or (B) is made in a complaint or other document
filed in a lawsuit or other proceeding, if such filing is made under seal. 

  

	 	3.4	 Third Party Agreements. The Advisor acknowledges that the Company from time to time may have agreements
with other persons or with U.S. federal, state, or local government bodies, or agencies thereof, that impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the
confidential nature of such work. The Advisor agrees to be bound by all such obligations and restrictions that are known to Advisor and to take all action necessary to discharge the obligations of the Company under such agreements.

  

	 	3.5	 Destruction of Proprietary Information. If the Company issues a written request to the Advisor to
destroy all Proprietary Information in the Advisor’s possession, then within ten (10) days of such written request, the Advisor shall destroy all such Proprietary Information and shall certify in writing to the Company that such
destruction has occurred. 

  

	4.	 Inventions and Company Intellectual Property. 

 

	 	4.1	 All inventions, discoveries, data, technology, designs, creations, deliverables, documents, information,
formulations, products, ideas, trade secrets, know-how, materials, processes, research, innovations and improvements (whether or not patentable, whether or not copyrightable, and whether or not registrable as
a trademark or service mark), including all intellectual property rights therein, which are made, conceived, reduced to practice, created, written, designed or developed by the Advisor, solely or jointly with others and whether during normal
business hours or otherwise, that (i) are related to the Company, (ii) arising from or related to the performance of Services, or (iii) resulting or derived from Proprietary Information

	 	
(collectively under clauses (i) through (iii), “Inventions”), shall be the sole property of the Company and shall be considered “works made for hire” within
the meaning of the United States Copyright Act. The Company shall be the exclusive owner of all worldwide right, title and interest in and to such Inventions, including, but not limited to, all proprietary and intellectual property rights therein.
To the extent any Invention may for any reason not be deemed a work made for hire, or to the extent any right, title or interest in or to such Invention, or any part thereof, may not by operation of law vest in the Company, then the Advisor hereby
irrevocably assigns all right, title and interest worldwide in and to all Inventions and any and all related patents, copyrights, trademarks, trade names, and other industrial and intellectual property rights and applications therefor, to the
Company and appoints any officer of the Company as the Advisor’s duly authorized attorney to execute, file, prosecute and protect the same before any government agency, court or authority. The Advisor hereby waives all claims to moral rights in
any Invention. 

  

	 	4.2	 The Advisor agrees that if, in the course of performing the Services, the Advisor incorporates or intends to
incorporate into any Invention developed under this Agreement any preexisting invention, improvement, development, concept, discovery or other proprietary information owned by the Advisor or in which the Advisor has an interest (“Prior
Inventions”), (i) the Advisor will inform the Company, in writing before incorporating such Prior Inventions into any Invention, and (ii) the Company is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable,
transferable worldwide license with the right to grant and authorize sublicenses, to make, have made, modify, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare derivative works of, display, perform, and otherwise
exploit such Prior Inventions, without restriction, including, without limitation, as part of or in connection with such Invention, and to practice any method related thereto. The Advisor will not incorporate any invention, improvement, development,
concept, discovery or other proprietary information owned by any third party into any Invention without the Company’s prior written permission. 

  

	 	4.3	 Upon the request of the Company and at the Company’s expense, the Advisor shall execute such further
assignments, documents and other instruments as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the Company in applying for, obtaining and enforcing patents or copyrights or other rights in
the United States and in any foreign country with respect to any Invention. 

  

	 	4.4	 The Advisor shall promptly disclose to the Company all Inventions and will maintain adequate and current
written records (in the form of notes, sketches, drawings and as may be specified by the Company) to document the conception and/or first actual reduction to practice of any Invention. Such written records shall be available to and remain the sole
property of the Company at all times. 

	5.	 Other Obligations; Indemnification and Liabilities. 

 

	 	5.1	 Other Obligations. The Advisor represents that the Advisor’s retention as a Advisor with the
Company and the Advisor’s performance under this Agreement does not, and shall not, breach any agreement that obligates the Advisor to keep in confidence any trade secrets or confidential or proprietary information of the Advisor or of any
other party or to refrain from competing, directly or indirectly, with the business of any other party. The Advisor shall not disclose to the Company any trade secrets or confidential or proprietary information of any other party. The Advisor
represents and warrants that the Advisor will not incorporate into any deliverables provided to the Company any intellectual property that belongs to a third party, or otherwise use any intellectual property belonging to a third party in connection
with providing the Services hereunder, in either case without the express, prior written approval of the Company. 

  

	6.	 Miscellaneous. 

 

	 	6.1	 Entire Agreement. This Agreement, along with any exhibits to this Agreement, constitutes the entire
agreement between the Company and the Advisor, and supersedes all previous oral or written agreements, regarding the Services to be provided to the Company by the Advisor; provided, however, this Agreement does not in any way merge with or supersede
the surviving provisions of the Employment Agreement, the Equity Documents, or the Separation Agreement. 

  

	 	6.2	 Remedies. The Advisor acknowledges that any breach of the provisions of Section 3 or
Section 4 of this Agreement shall result in serious and irreparable injury to the Company for which the Company cannot be adequately compensated by monetary damages alone. The Advisor agrees, therefore, that, in addition to any other
remedy it may have at law or in equity, the Company shall be entitled to enforce the specific performance of this Agreement by the Advisor and to seek both temporary and permanent injunctive relief (to the extent permitted by law) without the
necessity of proving actual damages or posting security therefor. 

  

	 	6.3	 Amendment and Waiver. Any term of this Agreement may be amended or waived only by a writing that
specifically references this Agreement and that is executed by both parties. The failure to enforce any provision of this Agreement by a party shall not constitute a waiver of any term hereof by that party. 

 

	 	6.4	 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts, excluding its body of law controlling conflict of laws. Any legal action or proceeding arising under this Agreement will be brought exclusively in the federal or state courts located in Connecticut and the parties
irrevocably consent to the personal jurisdiction and venue therein. 

	 	6.5	 Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, both parties
and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to its assets or business, provided, however, that the obligations of the Advisor are personal and shall
not be assigned by the Advisor without the prior written consent of the Company. 

  

	 	6.6	 Use of Other Names. Except as required by law, before either party uses the name of the other party or
refers to the existence or terms of this Agreement in any publication or other public disclosure, it shall obtain prior written permission from the other party. 

 

	 	6.7	 Notices. Any notices required or permitted hereunder shall be in writing and given to the appropriate
party at such address or addresses as either party shall designate to the other in accordance with this Section. A notice shall be deemed given upon personal delivery to the appropriate address, one business day after the date of transmission if
sent by facsimile or electronic transmission (with confirmation of transmission), or one business day after the date of shipping if sent by an internationally recognized overnight courier. Any party may change its address for notification purposes,
without amending this Agreement, upon advance written notice to the other party delivered in accordance with this paragraph. 

  

	 	6.8	 Severability. If any provisions of this Agreement are held to be unenforceable under applicable law by a
court of competent jurisdiction, the parties agree to renegotiate on a good faith basis the unenforceable provision. If the parties cannot reach a mutually agreeable and enforceable replacement for the unenforceable provision, then the unenforceable
provision shall be severed and all remaining provisions shall continue in full force and effect. 

  

	 	6.9	 Survival. Sections 1.6, 3, 4, 5, and 6 of this Agreement shall survive the
expiration or termination of this Agreement. 

  

	 	6.10	 Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the
corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 

  

	 	6.11	 Counterparts. This Agreement may be executed in two counterparts, each of which shall be deemed an
original, and all of which together shall constitute one instrument. This Agreement may be executed via facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen.

 [Signature Page Follows] 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the day and
year set forth above. 
  

							
	GEMINI THERAPEUTICS SUB, INC.	 		 	JASON MEYENBURG
				
	By:	 	/s/ Georges Gemayel	 		 	/s/ Jason Meyenburg
	Name:	 	Georges Gemayel	 		 	
	Title:	 	Executive Chair	 		 	

 Exhibit A 

Services 
 The Advisor shall provide the
following Services: 
  

	 	•	 	 General consulting and advisory services in support of the Company’s business activities.

 Exhibit B 

Advisory Fees 
 As compensation for
Services described in Exhibit A, the Company will pay the Advisor at the rate of $500 per hour. The Company and Advisor agree that Advisor shall perform Services only as requested by the Company and that the number of hours of Services to be
performed by Advisor shall be mutually agreed upon by the parties prior to such Services being performed. 
 The Advisor shall maintain a detailed
accounting of hours worked and the Advisor shall invoice the Company once per each thirty (30)-day period beginning with the effective date for services provided. Compensation for invoiced services shall be
payable by the Company within thirty (30) days of receipt of said invoice and supporting documentation.Exhibit 10.1

 

ANI PHARMACEUTICALS,
INC.

 

EXECUTIVE INCENTIVE
BONUS PLAN

 

1.           
PURPOSE

 

The purpose of the ANI Pharmaceuticals,
Inc. Executive Incentive Bonus Plan (as amended from time to time, the “Plan”) is to motivate and reward eligible
employees for their contributions toward the achievement of certain Performance Goals (as defined below) by ANI Pharmaceuticals, Inc.
(together with any of its Affiliates, the “Company”).

 

2.           
DEFINITIONS

 

The following definitions
shall be applicable throughout the Plan:

 

(a)         
“Affiliate” means a Parent, a Subsidiary or any corporation or other entity that, directly or indirectly
through one or more intermediaries, controls, or is controlled by, or is under common control with, the Company.

 

(b)         
“Applicable Laws” means all applicable laws, rules, regulations and requirements, including, but not
limited to, all applicable U.S. federal or state laws, rules and regulations, the rules and regulations of any stock exchange or quotation
system on which the Company’s common stock is listed or quoted, and the applicable laws, rules and regulations of any other country
or jurisdiction where Awards are, or will be, granted under the Plan or Participants reside or provide services to the Company or any
Affiliate, as such laws, rules, and regulations shall be in effect from time to time.

 

(c)          
“Award” means a cash incentive payable under the Plan to a Participant with respect to a Performance
Period.

 

(d)         
“Board” means the Board of Directors of the Company, as constituted from time to time.

 

(e)         
“Code” means the Internal Revenue Code of 1986, as amended. Reference to a specific section of the Code
or regulation thereunder shall include such section or regulation, any valid regulation promulgated under such section, and any comparable
provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.

 

(f)           
“Committee” means the Compensation Committee of the Board unless another Committee is designated by the
Board. The members of any Committee designated by the Board shall be appointed from time to time by, and serve at the pleasure of, the
Board. Any member of any such Committee may resign at any time by notice in writing mailed or delivered to the Secretary of the Company.
As of the Effective Date, the Plan shall be administered by the Compensation Committee of the Board.

 

(g)         
“Effective Date” means February 23, 2022.

 

(h)         
“Participant” means any officer or employee of the Company who is designated as a Participant by the
Committee.

 

    

     

    

 

(i)           
 “Performance Goal” means a formula or standard determined by the Committee with respect to each Performance
Period based on one or more of the following criteria and any adjustment(s) thereto established by the Committee: (i) sales or non-sales
revenue; (ii) return on revenue; (iii) operating income; (iv) income or earnings including operating income; (v) income or earnings before
or after taxes, interest, depreciation and/or amortization; (vi) income or earnings from continuing operations; (vii) net income; (viii)
pre-tax income or after-tax income; (ix) net income excluding amortization of intangible assets, depreciation and impairment of goodwill
and intangible assets and/or excluding charges attributable to the adoption of new accounting pronouncements; (x) raising of financing
or fundraising; (xi) project financing; (xii) revenue or revenue backlog; (xiii) gross margin; (xiv) operating margin or profit margin;
(xv) capital expenditures, cost targets, reductions and savings and expense management; (xvi) return on assets (gross or net), return
on investment, return on capital, or return on stockholder equity; (xvii) cash flow, operating cash flow, free cash flow, cash flow return
on investment (discounted or otherwise), net cash provided by operations, or cash flow in excess of cost of capital; (xviii) performance
warranty and/or guarantee claims; (xix) stock price or total stockholder return; (xx) earnings or book value per share (basic or diluted);
(xxi) economic value created; (xxii) pre-tax profit or after-tax profit; (xxiii) strategic business criteria, consisting of
one or more objectives based on meeting specified market penetration or market share, completion of strategic agreements such as licenses,
joint ventures, acquisitions, and the like, geographic business expansion, objective customer satisfaction or information technology goals,
intellectual property asset metrics; (xxiv) objective goals relating to divestitures, joint ventures, mergers, acquisitions and similar
transactions; (xxv) objective goals relating to staff management, results from staff attitude and/or opinion surveys, staff satisfaction
scores, staff safety, staff accident and/or injury rates, compliance, headcount, performance management, completion of critical staff
training initiatives; (xxvi) objective goals relating to projects, including project completion, timing and/or achievement of milestones,
project budget, technical progress against work plans; (xxvii) enterprise resource planning; and (xxix) non-GAAP EBITDA as prepared for
external presentation, in conjunction with debt covenants, or definitions approved by the Committee from time to time. Awards issued to
Participants may take into account other criteria (including subjective criteria). Performance Goals may differ from Participant to Participant,
Performance Period to Performance Period and from Award to Award. Any criteria used may be measured, as applicable, (A) in absolute terms,
(B) in relative terms (including, but not limited to, any increase (or decrease) over the passage of time and/or any measurement against
other companies or financial or business or stock index metrics particular to the Company), (C) on a per share and/or share per capita
basis, (D) against the performance of the Company as a whole or against any Affiliate(s), particular segment(s), business unit(s) or product(s)
of the Company or individual project company, (E) on a pre-tax or after-tax basis, (F) on a GAAP or non-GAAP basis, and/or (G) using an
actual foreign exchange rate or on a foreign exchange neutral basis.

 

(j)           
“Parent” means any corporation (other than the Company) in an unbroken chain of corporations ending with
the Company if each of the corporations other than the Company owns stock possessing fifty percent (50%) or more of the total combined
voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Parent
on a date after the adoption of the Plan shall be considered a Parent commencing as of such date.

 

(k)          
“Performance Period” means the Company’s fiscal year, multiple fiscal years or any other period
longer or shorter than one fiscal year, as determined by the Committee, in its sole discretion. The Committee may establish different
Performance Periods for different Participants, and the Committee may establish concurrent or overlapping Performance Periods.

 

    - 2 -

     

    

 

(l)           
 “Subsidiary” means any corporation (other than the Company) in an unbroken chain of corporations beginning
with the Company if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent
(50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation
that attains the status of a Subsidiary on a date after the adoption of the Plan shall be considered a Subsidiary commencing as of such
date.

 

(m)        
“Tax-Related Items” means any or all applicable national, local or other income tax, social insurance
or other social contributions, national insurance, social security, payroll tax, fringe benefit tax, payment on account, withholding,
required deductions or payments or other tax-related items arising in relation to a Participant’s participation in the Plan and
legally applicable to a Participant.

 

3.           
ADMINISTRATION

 

The Plan shall be administered
by the Committee, which shall have the discretionary authority to interpret the provisions of the Plan, including all decisions on eligibility
to participate, the establishment of Performance Goals, the amount of Awards payable under the Plan, and the payment of Awards. The Committee
shall also have the discretionary authority to establish rules under the Plan so long as such rules do not explicitly conflict with the
terms of the Plan and any such rules shall constitute part of the Plan. The decisions of the Committee shall be final and binding on all
parties making claims under the Plan. The Committee, in its sole discretion and on such terms and conditions as it may provide, may delegate
all or part of its authority and powers under the Plan to one or more directors and/or officers of the Company.

 

4.           
ELIGIBILITY

 

Officers and other key employees
of the Company designated by the Committee to participate in the Plan shall be eligible to participate in this Plan, provided the Committee
has not, in its sole discretion, withdrawn such designation and he or she meets the following conditions:

 

(a)         
is a part-time or full-time regular employee of the Company as of the last day of the applicable Performance Period; and

 

(b)         
is not subject to disciplinary action, is in good standing with the Company and is not subject to a performance improvement plan.

 

5.           
AMOUNT OF AWARDS

 

With respect to each Participant,
the Committee will establish one or more Performance Periods, an individual Participant incentive target (which may be, but is not required
to be, based on the Participant’s base salary) for each Performance Period and the Performance Goal(s) to be met during such Performance
Period(s).

 

Except as otherwise
required by Applicable Laws or as determined by the Committee, base salary shall not include salary paid during any paid leave of
absence or any variable forms of compensation including, but not limited to, overtime, on-call pay, lead premiums, shift
differentials, bonuses, incentive compensation, commissions, stock options, restricted stock units, restricted stock, stock
appreciation rights, stock bonuses, expense allowances or reimbursements. Nothing in the Plan, or arising as a result of a
Participant’s participation in the Plan, shall prevent the Company from changing a Participant’s base salary at any time
based on such factors as the Company shall in its discretion determine appropriate.

 

    - 3 -

     

    

 

Awards may be pro-rated on
any basis determined appropriate in the Committee’s sole discretion, including, but not limited to, in connection with transfers
to new positions or new locations, new hires, Participants on a leave of absence for all or any portion of Performance Periods, or Participants
working less than full-time. The Committee reserves the right, in its sole discretion, to increase, reduce or eliminate the amount of
an Award otherwise payable to a Participant with respect to any Performance Period.

 

6.           
PAYMENT OF AWARDS

 

(a)         
Unless otherwise determined by the Committee, a Participant must be actively employed and in good standing with the Company on
the date the Award is paid. The Committee may make exceptions to this requirement in the case of retirement, death or disability, an unqualified
leave of absence or under other circumstances, as determined by the Committee in its sole discretion.

 

(b)         
Payment of each Award shall be made as soon as administratively practicable but in any event no later than the 15th day of the
third month following the end of the Performance Period during which the Award was earned (in the case of any Performance Period based
on a fiscal year, by March 15th thereafter). Each Award shall be paid in cash (or its equivalent) in a single lump sum unless such amounts
are otherwise deferred in accordance with Section 6(c).

 

(c)          
The Committee, in its sole discretion, may permit a Participant to defer receipt of the payment of cash that would otherwise be
delivered to a Participant under the Plan. Any such deferral elections shall be subject to such rules and procedures as shall be determined
by the Committee in its sole discretion.

 

7.           
GENERAL

 

(a)         
Tax Withholding. The Company shall have the right to deduct from all Awards any Tax-Related Items, and any other deductions,
required to be withheld with respect to such payments. The Company also may withhold such amounts from any other amount payable by the
Company or any Affiliate to the Participant, subject to compliance with Applicable Laws.

 

(b)         
Section 409A of the Code. To the extent that any Award under the Plan is subject to Section 409A of the Code, the terms
and administration of such Award shall comply with the provisions of such section and good faith reasonable interpretations thereof, and,
to the extent necessary to achieve compliance, shall be modified, replaced or terminated at the discretion of the Committee. In no event
will the Company reimburse a Participant for any taxes or other penalties that may be imposed on the Participant as a result of Section 409A
of the Code.

 

(c)          
Claims to Awards and Employment Rights. Nothing in the Plan shall confer on any Participant the right to continued employment
with the Company or any of its Affiliates, or affect in any way the right of the Company or of any Affiliate to terminate the Participant’s
employment at any time, and for any reason, or to change the Participant’s responsibilities. Awards represent unfunded and unsecured
obligations of the Company and a holder of any right hereunder in respect of any Award shall have no rights other than those of a general
unsecured creditor to the Company.

 

    - 4 -

     

    

 

(d)         
 Beneficiaries. To the extent the Committee permits beneficiary designations, any payment of Awards under the Plan to a
deceased Participant shall be paid to the beneficiary duly designated by the Participant in accordance with the Company’s practices.
If no such beneficiary has been designated or survives the Participant, payment shall be made to the Participant’s legal representative,
legal beneficiary or estate, as applicable. A beneficiary designation may be changed or revoked by a Participant at any time, provided
the change or revocation is filed with the Committee prior to the Participant’s death.

 

(e)         
Non-Transferability. A person’s rights and interests under the Plan, including any Award previously made to such person
or any amounts payable under the Plan, may not be sold, assigned, pledged, transferred or otherwise alienated or hypothecated except,
in the event of a Participant’s death, to a designated beneficiary as provided in the Plan, or in the absence of such designation,
by will or the laws of descent and distribution.

 

(f)           
Successor. All obligations of the Company under the Plan, with respect to Awards granted hereunder, shall be binding on
any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation,
or otherwise, of all or substantially all of the business or assets of the Company.

 

(g)         
Limitation of Liability. Each person who is or has been a member of the Committee and each employee of the Company or an
Affiliate who is delegated a duty under the Plan shall be indemnified and held harmless by the Company from and against any loss, cost,
liability or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim, action,
suit or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action or failure to act under
the Plan and against and from any and all amounts paid by him or her in satisfaction of judgment in any such action, suit or proceeding
against him or her, provided such loss, cost, liability or expense is not attributable to such person’s willful misconduct. Any
person seeking indemnification under this provision shall give the Company prompt notice of any claim and shall give the Company an opportunity,
at its own expense, to handle and defend the same before the person undertakes to handle and defend such claim on his or her own behalf.
The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled,
including under the Company’s Articles of Incorporation or Bylaws, as a matter of Applicable Laws, or otherwise, or any power that
the Company may have to indemnify them or hold them harmless.

 

(h)         
Clawback/Recovery. The Committee may specify in an agreement that the Participant’s rights, payments, and/or benefits
with respect to an Award will be subject to reduction, cancellation, forfeiture, and/or recoupment upon the occurrence of certain specified
events, in addition to any applicable vesting, performance or other conditions and restrictions of an Award. Notwithstanding any provisions
to the contrary under this Plan, an Award granted under the Plan shall be subject to the Company’s clawback policy as may be established
and/or amended from time to time. The Committee may require a Participant to forfeit or return to and/or reimburse the Company for any
amounts paid with respect to an Award, pursuant to the terms of such Company policy or as necessary or appropriate to comply with Applicable
Laws.

 

(i)           
Expenses. The expenses of administering the Plan shall be borne by the Company.

  

(j)           
 Titles and Headings. The titles and headings of the sections in the Plan are for convenience of reference only, and in
the event of any conflict, the text of the Plan, rather than such titles or headings, shall control.

 

(k)          
Governing Law. The validity, construction, and effect of the Plan, any rules and regulations relating to the Plan, and any
Award shall be determined in accordance with the laws of the State of Delaware (without giving effect to principles of conflicts of laws
thereof) and applicable federal law.

 

(l)           
Amendment and Termination. The Committee may terminate the Plan at any time, provided such termination shall not affect
the payment of any Awards accrued under the Plan prior to the date of the termination. The Committee may, at any time, or from time to
time, amend or suspend and, if suspended, reinstate, the Plan in whole or in part; provided, however, that any amendment of the Plan shall
be subject to the approval of the Company’s stockholders to the extent required to comply with Applicable Laws.

 

* * *

 

    - 5 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]